Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma

Cancer Letters

Volumn 150, Issue 2, 2000, Pages 165-170

  Katsama, A ^a   Sourvinos, G ^a   Zachos, G ^b   Spandidos, D A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

BRCA1; BRCA2; Breast cancer; Heterozygosity; TP53

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; PROTEIN P53;

ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; NEOPLASM PROTEINS; TRANSCRIPTION FACTORS;

EID: 0033994345     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00386-9     Document Type: Article

References (27)

1. Black D.M. The genetics of breast cancer. Eur. J. Cancer. 30A:1994;1957-1961.
2. Miki Y., Swensen J., Shattuck-Eidens K., Futreal P.A., Harshman K., Tavtigian K., Liu Q., Cochran C., Bennett L.M., Ding W., Bell R., Rosenthal J., Hussey C., Tran T., McClure M., Frye C., Hattier T., Phelps R., Haugen-Strano A., Katcher H., Yakumo K. Z. Gholami, D. Shaffer, S. Stone, S. Bayer, C. Wray, R. Bogden, P. Dayananth, J. Ward, P. Tonin, S. Narod, P.K. Bristow, F.H. Norris, L. Helvering, P. Morrison, P. Rosteck, M. Lai, J.C. Barrett, C. Lewis, S. Nehausen, L. Cannon-Albright, D. Goldgar, R. Wiseman, A. Kamb, M.H. Skolnick, A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66-71.
3. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 378:1995;789-792.
4. Tavtigian S.V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., Merajver S., Thorlacius S., Offit K., Stoppa-Lyonnet D., Belanger C., Bell R., Berry S., Bogden R., Chen Q., Davis T., Dumont M., Frye C., Hattier T., Jammulapati S., Janecki T., Jiang P., Kehrer R., Leblanc J.F., Mitchell J.T., McArthur-Morrison J., Nguyen K., Peng Y., Samson C., Schroeder M., Synder S.C., Steele L., StringFellow M., Stroup C., Swedlund B.C., Swensen J., Teng D., Thomas A., Tran T., Tran T., Tranchant M., Weaver-Feldhaus J., Wong A.K.C., Shizuya H., Eyfjord J.E., Cannon-Albright L., Labrie L., Skolnick M.H., Weber B., Kamb A., Goldgar D.E. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet. 12:1996;333-337.
5. Lancaster J., Wooster R., Mangion J., Phelan C.M., Cochran C., Gumbs C., Seal S., Barfoot R., Collins N., Bignell G., Patel S., Hamoudi R., Larsson C., Wiseman R.W., Berchuck A., Iglehart J.D., Marks J.R., Ashworth A., Stratton M.R., Futreal P.A. BRCA2 mutations in primary breast and ovarian cancers. Nat. Genet. 13:1996;238-240.
6. Beckmann M.W., Picard F., An H.X., van Roeyen C.R., Dominik S.I., Mosny D.S., Schnurch H.G., Bender H.G., Niederacher D. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br. J. Cancer. 73:1996;1220-1226.
7. Cox L.S., Hupp T., Midgley C.A., Lane D.P. A direct effect of activated human p53 on nuclear DNA replication. EMBO J. 14:1995;2099-2105.
8. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
9. Bergh J., Norberg T., Sjogren S., Lindgren A., Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med. 1:1995;1029-1034.
10. Saitoh S., Cunningham J., De Vries E.M., McGovern R.M., Schroeder J.J., Hartmann A., Blaszyk H., Wold L.E., Schaid D., Sommer S.S., Kovach J.S. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene. 9:1994;2869-2875.
11. Crook T., Crossland S., Crompton M.R., Osin P., Gusterson B.A. p53 mutations in BRCA1-associated familial breast cancer. Lancet. 350:1997;638-639.
12. Zachos G., Koumantaki E., Vareltzidis A., Spandidos D.A. Loss of heterozygosity of particular chromosome regions in human sporadic lesions. Br. J. Dermatol. 139:1998;974-977.
13. Sourvinos G., Kiaris H., Tsikkinis A., Vassilaros S., Spandidos D.A. Microsatellite instability and loss of heterozygosity in primary breast tumours. Tumor Biol. 18:1996;157-166.
14. Aaltonen L.A., Peltomaki P., Leach F.S., Sistonen P., Pylkanen L., Mecklin J.-P., Jarvinen H., Powell S.M., Jen J., Hamilton S.R., Petersen G.M., Kinzler K.W., Vogelstein B., De la Chapelle A. Clues to the pathogenesis of familial colorectal cancer. Science. 260:1993;812-816.
15. Eyfjord J.E., Thorlacius S., Steinarsdottir M., Valgardsdottir R., Ogmundsdottir H.M., Anamthawat-Jonsson K. p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res. 55:1995;646-651.
16. Eiriksdottir G., Barkardottir R.B., Agnarsson B.A., Johannesdottir G., Olafsdottir K., Egilsson V., Ingvarsson S. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers. Oncogene. 16:1998;21-26.
17. Liscia D.S., Morizio R., Venesio T., Palenzona C., Donadio M., Callahan R. Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene. Br. J. Cancer. 80:1999;821-826.
18. Silva J.M., Gonzalez R., Provencio M., Dominguez G., Garcia J.M., Gallego I., Palacio J., Espana P., Bonilla F. Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer. Breast Cancer Res. Treat. 53:1999;9-17.
19. Kerangueven F., Allione F., Noguchi T., Adelaide J., Sobol H., Jacquemier J., Birnhaum D. Patterns of loss of heterozygosity at loci from chromosome arm 13q suggests a possible involvement of BRCA2 in sporadic breast tumours. Genes Chromosomes Cancer. 13:1995;291-294.
20. Van den Berg J., Johannsson O., Hakansson S., Olsson H., Borg A. Allelic loss at chromosome 13q12-13 is associated with poor prognosis in familial and sporadic breast cancer. Br. J. Cancer. 74:1996;1615-1619.
21. Hamann U., Herbold C., Costa S., Solomayer E.F., Kaufmann M., Bastert G., Ulmer H.U., Frenzel H., Komitowski D. Allelic imbalance on chromosome 13q: evidence for the involvement of BRCA2 and RB1 in sporadic breast cancer. Cancer Res. 56:1996;1988-1990.
22. Soenen V., Preudhomme C., Roumier C., Daudignon A., Lai J.L., Fenaux P. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood. 91:1998;1008-1015.
23. Li X., Tsuji T., Wen S., Mimura Y., Sasaki K., Shinozaki F. Detection of numeric abnormalities of chromosome 17 and p53 deletions by fluorescence in situ hybridization in pleomorphic adenomas and carcinomas in pleomorphic adenoma. Correlation with p53 expression. Cancer. 79:1997;2314-2319.
24. Tirkkonen M., Johannsson O., Agnarsson B.A., Olsson H., Ingvarsson S., Karhu R., Tanner M., Isola J., Barkardottir R.B., Borg A., Kallioniemi O.P. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 57:1997;1222-1227.
25. Holt J.T., Thompson M.E., Szabo C., Robinson-Benion C., Arteaga C.L., King M.C., Jensen R.A. Growth retardation and tumour inhibition by BRCA1. Nat. Genet. 12:1996;298-302.
26. Sourvinos G., Spandidos D.A. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumours. Biochem. Biophys. Res. Commun. 245:1998;75-80.
27. Yee C.J., Roodi N., Verrier C.S., Parl F.F. Microsatellite instability and loss of heterozygosity in breast cancer. Cancer Res. 54:1994;1641-1644.